- NCIt
- C116915
Loading cancer entity…
Loading cancer entity…
Clinical trials
47 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06482515 | Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue | recruiting | Phase 2 | 96 | University of Maryland, BaltimoreOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06510699 | Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial(PRAGMATIC) | recruiting | Phase 2 | 104 | The University of QueenslandOTHER | 2 | Apr 16, 2026 | clinicaltrials |
| NCT05873205 | Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation | active not recruiting | Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07148180 |
Data updated 22 days agoSource updated Jun 5, 2026source: clinicaltrials
| A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax |
| recruiting |
| Phase 1 / Phase 2 |
| 31 |
| Jacqueline Garcia, MDOTHER |
| 1 |
| Feb 5, 2026 |
| clinicaltrials |
| NCT06119685 | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | recruiting | Phase 1 / Phase 2 | 128 | Indapta Therapeutics, INC.INDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT02361346 | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL(MT-3724NHL001) | terminated | Phase 1 / Phase 2 | 38 | Molecular Templates, Inc.INDUSTRY | 10 | Aug 18, 2022 | clinicaltrials |
| NCT00185640 | Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies | completed | Phase 2 | 303 | Stanford UniversityOTHER | 1 | Jun 29, 2021 | clinicaltrials |
| NCT00185692 | Allogeneic Transplantation From Related Haploidentical Donors | completed | Phase 2 | 16 | Stanford UniversityOTHER | 1 | Dec 4, 2019 | clinicaltrials |
| NCT00185614 | Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma | completed | Phase 2 | 63 | Wen-Kai WengOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT00185796 | TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD | completed | Phase 2 | 77 | Stanford UniversityOTHER | 1 | Mar 18, 2015 | clinicaltrials |
| NCT00962494 | Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors | completed | Phase 2 | 585 | Stanford UniversityOTHER | 2 | Feb 7, 2013 | clinicaltrials |
| NCT00230321 | A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS) | completed | Phase 1 / Phase 2 | 21 | Peter L GreenbergOTHER | 1 | Feb 4, 2013 | clinicaltrials |